CHEBI:3437 - carteolol

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name carteolol
ChEBI ID CHEBI:3437
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
more structures >>
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C16H24N2O3
Net Charge 0
Average Mass 292.37340
Monoisotopic Mass 292.179
InChI InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
InChIKey LWAFSWPYPHEXKX-UHFFFAOYSA-N
SMILES CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12
Roles Classification
Biological Role(s): beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
sympatholytic agent
Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS).
Application(s): beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
antihypertensive agent
Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
sympatholytic agent
Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS).
antiglaucoma drug
Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
anti-arrhythmia drug
A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing carteolol (CHEBI:3437) has role β-adrenergic antagonist (CHEBI:35530)
carteolol (CHEBI:3437) has role anti-arrhythmia drug (CHEBI:38070)
carteolol (CHEBI:3437) has role antiglaucoma drug (CHEBI:39456)
carteolol (CHEBI:3437) has role antihypertensive agent (CHEBI:35674)
carteolol (CHEBI:3437) has role sympatholytic agent (CHEBI:66991)
carteolol (CHEBI:3437) is a quinolone (CHEBI:23765)
carteolol (CHEBI:3437) is a secondary alcohol (CHEBI:35681)
carteolol (CHEBI:3437) is conjugate base of carteolol(1+) (CHEBI:61202)
Incoming carteolol(1+) (CHEBI:61202) is conjugate acid of carteolol (CHEBI:3437)
IUPAC Name
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
INNs Sources
carteolol WHO MedNet
cartéolol WHO MedNet
carteolol ChemIDplus
carteololum WHO MedNet
Synonym Source
Carteolol KEGG COMPOUND
Manual Xrefs Databases
520 DrugCentral
C06874 KEGG COMPOUND
Carteolol Wikipedia
D07624 KEGG DRUG
DB00521 DrugBank
DE2302027 Patent
LSM-1541 LINCS
US3910924 Patent
View more database links
Registry Numbers Types Sources
1221735 Beilstein Registry Number Beilstein
51781-06-7 CAS Registry Number ChemIDplus
Last Modified
22 February 2017